Shares of Tilray TLRY rose 5.9% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 96.00% over the past year to ($0.02), which beat the estimate of ($0.21).
Revenue of $51,406,000 up by 0.60% from the same period last year, which missed the estimate of $54,880,000.
Outlook
Tilray hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Nov 09, 2020
Time: 05:00 PM
ET Webcast URL: http://public.viavid.com/player/index.php?id=141782
Technicals
52-week high: $24.10
52-week low: $2.43
Price action over last quarter: Up 47.04%
Company Description
Tilray, headquartered in Nanaimo, Canada, cultivates and sells medical and recreational cannabis through a portfolio of brands that include Canaca, Dubon, and Manitoba Harvest. The bulk of Tilray's sales are in Canada, but the company also sells CBD Products in the U.S. and exports medical cannabis globally from its production facilities in Canada and Portugal. Tilray also has a joint venture partnership with AB InBev to develop cannabis-infused drinks.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
